Bluejay diagnostics updates symphony il-6 regulatory strategy

Acton, mass., may 19, 2023 (globe newswire) --  bluejay diagnostics, inc. (nasdaq: bjdx) (“bluejay” or the “company”), a medical technology company developing rapid diagnostics on its symphony platform to improve patient outcomes in critical care settings, today announced an updated clinical and regulatory strategy for the symphony il-6 biomarker test to measure acuity in sepsis patients. the company plans to modify the clinical trials design to evaluate symphony il-6 as a tool to risk stratify hospitalized sepsis patients.
BJDX Ratings Summary
BJDX Quant Ranking